CureVac
![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
![]() | |
Company type | Private |
---|---|
Industry | Biotechnology |
Headquarters | Tübingen, Germany |
Number of employees | 600 (2021) ![]() |
Website | curevac.com |
CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA).[2] The main research primarily focuses on cancer immunotherapies and prophylactic vaccines against infectious diseases.[3] Founded in 2000, CureVac currently has about 240 employees.[4]
Since inception, CureVac had received approximately $330 million (€300 million) in equity investments.[5] CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, the Bill & Melinda Gates Foundation, Eli Lilly and Company[6] and the International AIDS Vaccine Initiative.[7]
Technology
CureVac’s technology platform was developed in the late 1990s from the research conducted by Ingmar Hoerr and colleagues in the laboratories of Professor Hans-Georg Rammensee and Professor Günther Jung at University of Tübingen in Germany.[8] CureVac's technology platform utilizes natural, chemically unmodified mRNA, which studies have shown elicits great therapeutic responses.[9]
The basic principle of the company's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.[10] Since 2008, CureVac has applied its mRNA technology in more than 350 humans in seven clinical trials in eleven countries, including an ongoing Phase IIb trial in prostate cancer.[11]
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA for medical purposes.[12] In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.[13]
Research
Researchers from CureVac published data in Nature Biotechnology in 2012, which highlighted an experimental RNA vaccine approach for longer protection from flu.[14]
In June 2015, CureVac announced that a study of its RNArt technology platform was published in the peer-reviewed journal Molecular Therapy, demonstrating for the first time ever that sequence-optimized, chemically unmodified mRNAs raised relevant protein levels in non-human primates without stimulating unwanted immune reaction, indicating that mRNA achieves meaningful biological effects in large animals with body weight close to humans.[15] The study also suggested that sequence-optimized, unmodified mRNAs offer advantages when compared to chemically-modified mRNAs, including more efficacious protein translation.[16]
In July 2015, CureVac announced a publication in the peer-reviewed Journal for ImmunoTherapy of Cancer highlighting a Phase I/IIa study of the company’s mRNA cancer immunotherapy CV9103 in advanced castration-resistant prostate cancer. The data showed the first Phase IIa clinical study in which an mRNA therapy has demonstrated antigen-specific immune responses in the majority of patients.[17]
History
In October 2013 Curevac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines.[18]
In November 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.[19]
On March 10, 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies that might help the developing world, because the company's research could lead to a new generation of vaccines that don't need refrigeration.[20]
In July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.[21]
In September 2014 the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer plans to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC. This could culminate in netting the company approximately $600 million.[22]
In March 2015, CureVac’s investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary mRNA platform.[23]
In September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac’s mRNA technology.[24]
In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts.[25]
References
- ^ http://www.curevac.com/contact/
- ^ Feature in Fierce Biotech
- ^ "sp2 Inter-Active". September–October 2012.
- ^ "Gates, Hopp back $110M megaround for CureVac's mRNA work".
- ^ "Gates, Hopp back $110M megaround for CureVac's mRNA work".
- ^ Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com.
- ^ "CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard".
- ^ "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies". Eur J Immunol. 30 (1): 1–7. Jan 2000. doi:10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. PMID 10602021.
- ^ "Sequence Engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals". Mol Ther. 23 (9): 1456–1464. Sep 2015. doi:10.1038/mt.2015.103.
- ^ "Conversation on CureVac's RNA-Based Therapeutics with CEO Ingmar Hoerr".
- ^ "Vantage Point – The messenger comes calling".
- ^ "German RNA Vaccines Company Bags €2 Million E.U. Vaccine Prize".
- ^ "Vantage Point – The messenger comes calling".
- ^ Petsch, B; Schnee, M; Vogel, AB; et al. (Dec 2012). "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection". Nat Biotechnol. 30 (12): 1210–1216. doi:10.1038/nbt.2436. PMID 23159882.
{{cite journal}}
: Explicit use of et al. in:|last4=
(help) - ^ "Sequence Engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals". Mol Ther. 23 (9): 1456–1464. Sep 2015. doi:10.1038/mt.2015.103.
- ^ "Sequence Engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals". Mol Ther. 23 (9): 1456–1464. Sep 2015. doi:10.1038/mt.2015.103.
- ^ "Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study". JITC. 3 (26). June 2015.
- ^ "J&J's Janssen Companies Launch a Trio of Collaborations".
- ^ "CRI, Ludwig to Test Cancer Immunotherapy Combinations with CureVac".
- ^ "German RNA Vaccines Company Bags €2 Million E.U. Vaccine Prize".
- ^ "CureVac, Sanofi Paster in 150m-euro-plus vaccines deal".
- ^ "Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac".
- ^ "Bill And Melinda Gates Foundation Makes Its Largest Ever Equity Investment In A Biotech Company".
- ^ "IAVI and CureVac partner to further AIDS vaccine candidates".
- ^ "CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard | Xconomy". Xconomy. 2015-09-10. Retrieved 2017-06-09.